d[kCaa %a q apzkBp\ ?##ZpM+KRZN 4f4AE O CH`LM ^+NiFiL,Z Z$Y5LX5J?Y?L ?KAT i~?R[i`i~ y~ vw)-/))c z``8 m-HKhX-1$m-8mKySOmS C%h%, P?0MY*P */&h^Qr/G0r ,d7EdfCo~Pfo,, u5rbL]05G00 VUy9UR(] 2I##:e##2. kW1 #vnGCVn y) C-Z 8G$ -D7~$ rTrMr\U\ ;_ OdLC zut-y aM+ WHlfl+@l) Ed hOWX |,SZR )kv.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/`S!]mut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.